336 related articles for article (PubMed ID: 33334221)
1. Target Validation Using PROTACs: Applying the Four Pillars Framework.
Nowak RP; Jones LH
SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
[TBL] [Abstract][Full Text] [Related]
2. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
4. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.
Chernobrovkin AL; Cázares-Körner C; Friman T; Caballero IM; Amadio D; Martinez Molina D
SLAS Discov; 2021 Apr; 26(4):534-546. PubMed ID: 33445986
[TBL] [Abstract][Full Text] [Related]
5. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
[TBL] [Abstract][Full Text] [Related]
6. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
7. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.
Simard JR; Lee L; Vieux E; Improgo R; Tieu T; Phillips AJ; Fisher SL; Pollock RM; Park E
SLAS Discov; 2021 Apr; 26(4):503-517. PubMed ID: 33430712
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
9. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
10. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
11. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
13. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
14. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
15. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
17. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
[TBL] [Abstract][Full Text] [Related]
18. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
19. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]